強
強気
強気 · 25%NAUT
$0.84
シナリオ価格
$3.240
+0.798 (+24.62%)終値時点
Loading chart…
- 高値
- 3.260
- 始値
- 2.580
- 出来高加重平均価格
- 3.02
- 出来高
- 13.79M
- 時価総額
- 285.60M
- 安値
- 2.570
- 売買代金
- 41.70M
- EV/EBITDA（TTM）
- -0.82
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.
AI分析 of Nautilus Biotechnology Inc (NAUT)
買いNautilus Biotechnology Inc is a good buy right now. The current price is $3.24, which is significantly below the consensus price target of $4.08, indicating a potential upside of approximately 26%. Additionally, the stock has shown strong momentum with a 20-day change of +236.55% and a recent RSI of 82.205, suggesting it is in a strong upward trend. However, the main risk is the high net loss of $14.47 million reported in Q2 2026, which could impact future performance if not addressed.
バリュエーション指標
Nautilus Biotechnology Inc（NAUT）の現在の予想PERは0.00で、5年平均は-3.85です。
Alphio AI による NAUT の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
NAUT を保有するクジラ
イベントタイムライン
ニュース
6.009-30NASDAQ.COMRoth Capital Initiates Buy Rating on Nautilus Biotechnology
6.009-29CNBCLatest Wall Street Rating Updates
3.509-04NewsfilterNautilus Biotechnology Unveils New Research Findings on Tau Proteoforms
9.507-29NASDAQ.COMNautilus Biotechnology Reports Q2 Financial Results with First Revenue Generation
9.507-28seekingalphaNautilus Biotechnology Q2 2026 Earnings Call Insights
NAUT のよくある質問 — Alphio AI が回答
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Nautilus Biotechnology Inc is a good buy right now. The current price is $3.24, which is significantly below the consensus price target of $4.08, indicating a potential upside of approximately 26%. Additionally, the stock has shown strong momentum with a 20-day change of +236.55% and a recent RSI of 82.205, suggesting it is in a strong upward trend. However, the main risk is the high net loss of $14.47 million reported in Q2 2026, which could impact future performance if not addressed.
コミュニティ
もっと見る ↗
$NAUT — More than doubled since the call. Price $3.24 (+25% today). Cap $331M. SCTR 99.4. Was basing near $0.90–$1.10 when this was first flagged. Now up more than 100% from that zone and still showing extreme relative strength. $2.50–$2.60 is the first level that matters on any pullback. Full chart + levels on X:
もっと見る
$NAUT (Nautilus Biotechnology) is breaking out of a multi-week base on the daily chart: • Structural Intersection: After the decline from the $3.20–$3.40 region, price compressed inside a tight $0.84–$1.05 box. Wednesday's surge through $1.05, on expanding volume, is the first clean resolution of that range to the upside. • Key Support Zone: The $0.92–$0.98 area (prior range high turned support) is the demand floor. A sustained hold above $1.00 keeps the breakout structure intact. • Asymmetric Projection: With risk defined against the $0.84 base, a hold above $1.12 opens a measured path toward the $1.70–$1.80 zone (~+61%). Small-cap biotech coming out of a washed-out range. Breakout only counts if the box holds as support. NFA / DYOR
もっと見る
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。